These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32246967)

  • 1. Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use.
    Bashyam AM; Cuellar-Barboza A; Masicampo EJ; Feldman SR
    J Am Acad Dermatol; 2020 Dec; 83(6):1773-1775. PubMed ID: 32246967
    [No Abstract]   [Full Text] [Related]  

  • 2. Remittive effect of Dupilumab in atopic dermatitis.
    Treister AD; Lio PA
    Dermatol Ther; 2018 Nov; 31(6):e12711. PubMed ID: 30253014
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib (Opzelura) for atopic dermatitis.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation.
    Murota H; Takeuchi S; Sugaya M; Tanioka M; Onozuka D; Hagihara A; Saeki H; Imafuku S; Abe M; Shintani Y; Kaneko S; Masuda K; Hiragun T; Inomata N; Kitami Y; Tsunemi Y; Abe S; Kobayashi M; Morisky DE; Furue M; Katoh N
    J Dermatol Sci; 2015 Sep; 79(3):279-87. PubMed ID: 26255207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis.
    Seo SR; Lee SG; Lee HJ; Yoon MS; Kim DH
    Acta Derm Venereol; 2017 Aug; 97(8):957-958. PubMed ID: 28512670
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
    Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical application of toll-like receptor 3 inhibitors ameliorates chronic allergic skin inflammation in mice.
    Tamagawa-Mineoka R; Ueta M; Arakawa Y; Yasuike R; Nishigaki H; Okuno Y; Hijikuro I; Kinoshita S; Katoh N
    J Dermatol Sci; 2021 Feb; 101(2):141-144. PubMed ID: 33262024
    [No Abstract]   [Full Text] [Related]  

  • 8. Topical corticosteroid phobia among parents of children with atopic dermatitis in a semirural area of Norway.
    Gustavsen HE; Gjersvik P
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):168. PubMed ID: 25174954
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency.
    Aubert-Wastiaux H; Moret L; Le Rhun A; Fontenoy AM; Nguyen JM; Leux C; Misery L; Young P; Chastaing M; Danou N; Lombrail P; Boralevi F; Lacour JP; Mazereeuw-Hautier J; Stalder JF; Barbarot S
    Br J Dermatol; 2011 Oct; 165(4):808-14. PubMed ID: 21671892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons.
    Frølunde AS; Thyssen JP; Deleuran M; Vestergaard C
    Am J Clin Dermatol; 2021 Nov; 22(6):775-783. PubMed ID: 34322849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three randomised phase I/IIa trials of 5% cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis.
    Peltonen JM; Pylkkänen L; Jansén CT; Volanen I; Lehtinen T; Laihia JK; Leino L
    Acta Derm Venereol; 2014 Jul; 94(4):415-20. PubMed ID: 24284985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.
    Tavakolpour S
    Dermatol Ther; 2016 Sep; 29(5):299. PubMed ID: 26800435
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical tacrolimus: a new therapy for atopic dermatitis.
    Russell JJ
    Am Fam Physician; 2002 Nov; 66(10):1899-902. PubMed ID: 12469964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal adherence factors in the treatment of pediatric atopic dermatitis.
    Fenerty SD; O'Neill JL; Gustafson CJ; Feldman SR
    JAMA Dermatol; 2013 Feb; 149(2):229-31. PubMed ID: 23426489
    [No Abstract]   [Full Text] [Related]  

  • 15. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment.
    Charman C
    Br J Dermatol; 2017 Oct; 177(4):1004-1005. PubMed ID: 28858382
    [No Abstract]   [Full Text] [Related]  

  • 16. An update on the topical and oral therapy options for treating pediatric atopic dermatitis.
    Glines KR; Stiff KM; Freeze M; Cline A; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2019 Apr; 20(5):621-629. PubMed ID: 30601075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review.
    Li AW; Yin ES; Antaya RJ
    JAMA Dermatol; 2017 Oct; 153(10):1036-1042. PubMed ID: 28724128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing Adherence with Topical Agents for Atopic Dermatitis.
    Patel NU; D'Ambra V; Feldman SR
    Am J Clin Dermatol; 2017 Jun; 18(3):323-332. PubMed ID: 28236222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.
    Samorano LP; Hanifin JM; Simpson EL; Leshem YA
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):522-3. PubMed ID: 25510643
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential.
    Vakharia PP; Silverberg JI
    BioDrugs; 2017 Oct; 31(5):409-422. PubMed ID: 28853008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.